Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Genge

Showing results (51-60 of 111) with videos related to

Pageof 12
Sort By:
Neuromuscular Disorders : NMD|March 11, 2026
A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophyCraig M Zaidman, Crystal Proud, Bing M Liao, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 1, 2025
Differentiating upper- and lower motor neuron diseases using automated acoustic analysisJustin Truong, Leif Simmatis, Timothy Pommée, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 28, 2023
Rare-variant and polygenic analyses of amyotrophic lateral sclerosis in the French-Canadian genomeJay P Ross, Fulya Akçimen, Calwing Liao, et al.
Neurology. Clinical Practice|September 3, 2021
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study DesignJames Berry, Benjamin Brooks, Angela Genge, et al.
The Lancet. Neurology|July 14, 2018
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trialRichard Hughes, Marinos C Dalakas, Ingemar Merkies, et al.
Neurology. Clinical Practice|November 22, 2019
Cerebral degeneration in amyotrophic lateral sclerosis: A prospective multicenter magnetic resonance spectroscopy studyOjas Srivastava, Chris Hanstock, Sneha Chenji, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 12, 2022
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trialPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 15, 2022
Motor cortex functional connectivity is associated with underlying neurochemistry in ALSAvyarthana Dey, Collin C Luk, Abdullah Ishaque, et al.
Neuroimage. Clinical|June 18, 2024
Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging studyHans-Peter Müller, Agessandro Abrahao, Christian Beaulieu, et al.
Pageof 12

Showing results (51-60 of 111) with videos related to

Sort By:
Pageof 12
Neuromuscular Disorders : NMD|March 11, 2026
A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophyCraig M Zaidman, Crystal Proud, Bing M Liao, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 1, 2025
Differentiating upper- and lower motor neuron diseases using automated acoustic analysisJustin Truong, Leif Simmatis, Timothy Pommée, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 28, 2023
Rare-variant and polygenic analyses of amyotrophic lateral sclerosis in the French-Canadian genomeJay P Ross, Fulya Akçimen, Calwing Liao, et al.
Neurology. Clinical Practice|September 3, 2021
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study DesignJames Berry, Benjamin Brooks, Angela Genge, et al.
The Lancet. Neurology|July 14, 2018
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trialRichard Hughes, Marinos C Dalakas, Ingemar Merkies, et al.
Neurology. Clinical Practice|November 22, 2019
Cerebral degeneration in amyotrophic lateral sclerosis: A prospective multicenter magnetic resonance spectroscopy studyOjas Srivastava, Chris Hanstock, Sneha Chenji, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 12, 2022
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trialPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 15, 2022
Motor cortex functional connectivity is associated with underlying neurochemistry in ALSAvyarthana Dey, Collin C Luk, Abdullah Ishaque, et al.
Neuroimage. Clinical|June 18, 2024
Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging studyHans-Peter Müller, Agessandro Abrahao, Christian Beaulieu, et al.
Pageof 12